Plus   Neg

Lam Research Q4 Profit Rises; Stock Up

Lam Research Corp. (LRCX) reported that its fourth-quarter net income increased to $696.67 million or $4.73 per share from $541.83 million or $3.51 per share in the prior year.

Non-GAAP net income for the latest-quarter was $704 million or $4.78 per share. Analysts polled by Thomson Reuters expected the company to report earnings of $4.14 per share for the quarter. Analysts' estimates typically exclude special items.

Quarterly revenue was $2.79 billion, up from $2.36 billion in the prior year. Analysts expected revenue of $2.72 billion for the quarter.

For the first-quarter, the company expects net income per share to be $5.06 plus or minus $0.40, non-GAAP net income of $5.15 plus or minus $0.40, and revenue of $3.1 billion plus or minus $200 Million.

LRCX closed Wednesday regular trading at $360.83 up $11.90 or 3.41 percent. In the after-hours, the stock further gained $10.07 or 2.79 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT